Operating income before deduction of amortization: Creative Medical Technology (CELZ)

Creative Medical Technology (CELZ) operates within a narrow regeneration segment where success depends on new patents. The EBITDA timeline visualizes profit dynamics, with 0.00 representing the most recent level. The company is developing cell therapy for orthopedics and sexual pathologies to replace surgical interventions. Unique proprietary treatment protocols for urological issues using the patient's own cells provide high pricing power.

CELZ Creative Medical Technology Profit before payment of interest, taxes and amortization (11/23/2025 - 11/10/2026)

Creative Medical Technology Holdings (CELZ) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Creative Medical Technology Holdings, Inc.|CELZ - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Creative Medical Technology|CELZ - Enterprise Value

- balance sheet equity data:

Accounting Value per Share Creative Medical Technology|CELZ - Company Book Value|Market Value to Book Value creativemedicaltechnology.com|CELZ - Company Total Assets

- business debt structure and liquidity details:

Debt to Capital Creative Medical Technology|CELZ - Long-Term Debt to Capital|Short-Term Debt to Capital Creative Medical Technology Holdings, Inc.|CELZ - Company Total Debt|Debt to Book Capital Creative Medical Technology|CELZ - Company Long-Term Debts|Short-Term Debt Volume Creative Medical Technology|Quick Liquidity creativemedicaltechnology.com

- earnings and multiples data:

CELZ - Net Profit|Expected Net Profit Creative Medical Technology|CELZ - Price to Earnings Ratio|Future Price to Earnings Multiple Creative Medical Technology Holdings, Inc.|CELZ - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Creative Medical Technology|CELZ - Operating profit EBITDA|Net earnings per one share for the last twelve months Creative Medical Technology|CELZ - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months creativemedicaltechnology.com|CELZ - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Creative Medical Technology

Fundamental company valuation:Creative Medical Technology CELZ

Manufactured product of Creative Medical Technology Holdings

Creative Medical Technology focuses on the development of cell therapy, where investments in clinical trials currently serve as the primary source of liquidity. By analyzing EBITDA cash flow, an investor can see the actual volume of operating cash inflows before non-cash expenses, allowing for the real-time assessment of systemic funding failures and the resilience of the business model to macroeconomic shocks.

Who Creative Medical Technology competes with

Mesoblast Pharma - Profit before payment of interest, taxes and amortization|LCTX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization surrozen.com SRZN|CCEL: Operating profit EBITDA|Operating profit before deduction of amortization FibroBiologics|Profit before payment of interest, taxes and amortization Longeveron Corp|BRTX: Income before deduction of interest, taxes and amortization